| Literature DB >> 29225901 |
Marianne Yardley1,2,3, Thor Ueland2,4,5,6, Pål Aukrust2,4,5,6,7, Annika Michelsen2,4, Elisabeth Bjørkelund1, Lars Gullestad1,2,8, Kari Nytrøen1,2.
Abstract
Background: The present study explored and compared the immediate responses in markers of inflammation and angiogenesis in maintenance heart transplant (HTx) recipients before, during and after sessions of high-intensity interval training (HIT) versus moderate-intensity continuous training (MICT). The study aimed to explain some of the trigger mechanisms behind HIT in HTx recipients.Entities:
Keywords: exercise therapy for cardiac transplant recipients; heart transplant; high intensity interval training[title]; inflammation; vascular endothelial growht factor
Year: 2017 PMID: 29225901 PMCID: PMC5708310 DOI: 10.1136/openhrt-2017-000635
Source DB: PubMed Journal: Open Heart ISSN: 2053-3624
Figure 1Illustration of the cross-over design of the study.
Figure 2A, Illustration of the moderate-intensity continuous exercise session with timing of the blood samples. B, Illustration of the high-intensity interval exercise session with timing of the blood samples.
Descriptive statistics; heart transplant recipients and healthy controls
| Variables* | HTx (n=14) | Healthy controls (n=5) | P value |
| Sex (% men) | 86 | 80 | 1.000 |
| Age (years) | 53 (13) | 52 (7) | 0.764 |
| In work (% yes) | 71 | 100 | 0.530 |
| Time after HTx (years) | 3 (2) | – | |
| Smoking (% never smoked) | 79 | 100 | 0.530 |
| Exercise variables | |||
| Vo2peak (mL/kg/min) | 31.0 (6.8) | 40.2 (2.7) | 0.001 |
| % of estimated Vo2 | 85 (17) | 111 (15) | 0.014 |
| Peak heart rate | 153 (17) | 182 (14) | 0.004 |
| RER | 1.16 (0.10, 1.22) | 1.23 (1.20, 1.24) | 0.087 |
| VE/VCo2slope | 24 (12) | 25 (3) | 0.791 |
| Peak respiration rate | 46 (9) | 49 (8) | 0.567 |
| O2pulse | 15.7 (3.1) | 17.9 (2.3) | 0.131 |
| Peak systolic BP | 211 (25) | 215 (20) | 0.744 |
| Peak diastolic BP | 92 (30) | 90 (9) | 0.824 |
| Self-reported physical activity | |||
| Exercise frequency (%) | 7/57/36 | 20/80/0 | 0.263 |
| Exercise duration (%) | 14/86 | 25/75 | 1.000 |
| Exercise intensity (%) | 21/72/7 | 0/75/25 | 0.416 |
| Meeting the recommendations for daily activity† (% yes) | 86 | 60 | 0.272 |
| Inactivity daily (hours) | 6 (3) | 8 (5) | 0.331 |
*Variables are presented as mean (SD) or median (1st quartile, 3rd quartile).
†≥30 min.
BP, blood pressure; HTx, heart transplant recipients; RER, respiratory equivalent rate; VE, ventilation.
Baseline values of inflammatory markers; heart transplant recipients and healthy controls
| Inflammatory biomarkers† | HTx | Healthy controls | P value |
| General inflammation | |||
| C reactive protein‡ | 4.0 | 1.7 | 0.687 |
| sTNFr1 | 3.07 | 2.18 | 0.026 |
| Vascular inflammation | |||
| von Willebrand factor§ | 187 | 111 | 0.156 |
| VCAM | 489 | 408 | 0.115 |
| Blood platelets | |||
| Platelet-derived growth factor | 1.97 | 2.87 | 0.559 |
| sCD40L | 0.98 | 1.59 | 0.070 |
| DKK-1 | 2.08 | 1.28 | 0.440 |
| Angiogenesis | |||
| Vascular endothelial growth factor-1 | 0.19 | 0.15 | 0.298 |
| Angiopoietin-2 | 1.30 | 1.47 | 0.823 |
| Tie-2 | 15.9 | 15.8 | 0.817 |
| Endostatin | 162 | 138 | 0.165 |
| Cardiokine/myokine | |||
| GDF-15 | 1.14 | 0.36 | 0.019 |
| ST2 | 17.5 | 22.4 | 0.247 |
| SPARC | 306 | 212 | 0.823 |
*P value ≤0.05 between groups.
†All variables are presented as median with (1st quartile, 3rd quartile) and measured in ng/mL serum if not otherwise stated. ‡Measured as μg/mL.
§Measured as per cent of pool.
DKK-1, Dickkopf-related protein 1; GDF-15, growth differentiation factor-15; HTx, heart transplant recipients; sCD40L, soluble CD40 ligand; SPARC, secreted protein acidic and rich in cysteine; ST2, interleukin 1 receptor-like 1; sTNFr1, soluble tumour necrosis factor receptor 1; Tie-2, tyrosine kinase with immunoglobulin-like and EGF-like domains 2; VCAM, vascular cell adhesion molecule.
Analysis of variance (ANOVA) results for all inflammatory markers in the heart transplant recipients
| Variables† n=14 HTx | Baseline‡ | 15 min | 30 min | 1 hour | 2 hours | Time | Group | Time×group | |
| General inflammation | |||||||||
| CRP§ | MICT | 3.40±1.10 | 2.85±0.80 | 2.74±0.78 | 2.47±0.61 | 2.93±0.69 | 0.601 | 0.362 | 0.422 |
| HIT | 4.10±0.96 | 3.9±0.94 | 3.58±0.88 | 3.46±0.83 | |||||
| sTNFr1¶ | MICT | 3.08±0.25 | 3.17±0.16 | 3.39±0.20 | 3.09±0.21 | 2.91±0.17 | <0.001** | 0.616 | 0.112 |
| HIT | 3.38±0.24 | 3.56±0.20 | 2.76±0.16 | 2.74±0.18 | |||||
| Vascular inflammation | |||||||||
| vWF†† | MICT | 191±31 | 117±17 | 131±20 | 138±23 | 173±28 | 0.175 | 0.044 | 0.075 |
| HIT | 179±29 | 239±48 | 151±26 | 151±23 | |||||
| VCAM | MICT | 511±36 | 527±36 | 486±29 | 458±29 | 468±26 | 0.069 | 0.672 | 0.422 |
| HIT | 495±23 | 507±32 | 446±20 | 460±25 | |||||
| Blood platelets | |||||||||
| PDGF | MICT | 2.08±0.22 | 2.48±0.33 | 2.72±0.33 | 2.22±0.28 | 2.17±0.21 | 0.002** | 0.162 | 0.690 |
| HIT | 2.78±0.40 | 3.00±0.43 | 2.33±0.24 | 2.33±0.30 | |||||
| sCD40L | MICT | 1.07±0.15 | 1.29±0.18 | 1.26±0.18 | 1.04±0.15 | 1.06±0.17 | <0.001** | 0.047 | 0.237 |
| HIT | 1.41±0.20 | 1.46±0.21 | 1.20±0.18 | 1.14±0.16 | |||||
| DKK-1 | MICT | 2.85±0.62 | 3.15±0.84 | 3.49±0.87 | 3.00±0.69 | 2.80±0.71 | 0.023** | 0.995 | 0.130 |
| HIT | 3.42±0.86 | 4.13±0.83 | 2.15±0.49 | 2.74±0.44 | |||||
| Angiogenesis | |||||||||
| VEGF-1¶ | MICT | 0.24±0.03 | 0.26±0.04 | 0.26±0.04 | 0.24±0.03 | 0.26±0.03 | 0.020** | 0.275 | 0.077* |
| HIT | 0.29±0.04 | 0.29±0.04 | 0.24±0.03 | 0.24±0.03 | |||||
| Ang-2¶ | MICT | 1.60±0.20 | 1.97±0.26 | 2.06±0.22 | 1.74±0.20 | 1.75±0.21 | <0.001** | 0.415 | 0.095* |
| HIT | 1.97±0.26 | 2.06±0.22 | 1.75±0.20 | 1.64±0.21 | |||||
| Tie-2 | MICT | 15.8±1.3 | 15.2±1.7 | 15.2±1.4 | 16.5±1.5 | 15.9±1.2 | 0.632 | 0.362 | 0.250 |
| HIT | 16.2±1.6 | 16.3±1.6 | 16.3±1.5 | 15.4±1.7 | |||||
| Endostatin | MICT | 165±11 | 166±12 | 169±12 | 163±9 | 159±11 | 0.206 | 0.167 | 0.594 |
| HIT | 184±14 | 183±13 | 170±13 | 162±12 | |||||
| Cardiokine/myokine | |||||||||
| GDF-15 | MICT | 1.03±0.11 | 1.20±0.19 | 1.19±0.19 | 1.12±0.19 | 1.10±0.19 | 0.206 | 0.041 | 0.067 |
| HIT | 1.10±0.11 | 1.15±0.11 | 0.96±0.11 | 0.93±0.08 | |||||
| ST2 | MICT | 20.3±2.0 | 20.0±1.9 | 20.5±2.1 | 20.1±1.8 | 20.7±2.2 | 0.425 | 0.112 | 0.228 |
| HIT | 22.4±2.2 | 22.7±2.2 | 21.2±2.0 | 21.3±2.4 | |||||
| SPARC | MICT | 319±57 | 486±60 | 433±95 | 297±64 | 294±63 | 0.020** | 0.122 | 0.745 |
| HIT | 391±79 | 491±84 | 336±60 | 328±56 | |||||
*P value <0.10.
**Significant P values <0.05.
†All variables are measured in ng/mL serum if not otherwise stated.
‡Results from 1 week ahead of first exercise session.
§Measured as μg/mL.
¶Analysis of variance was performed with log-transformed variables.
††Measured as per cent of pool.
Ang-2, angiopoietin-2; CRP, C reactive protein; DKK-1, Dickkopf-related protein 1; GDF-15, growth differentiation factor-15; HIT, high-intensity interval training; HTx, heart transplant recipients; MICT, moderate-intensity continuous training; PDGF, platelet-derived growth factor; sCD40L, soluble CD40 ligand; SPARC, secreted protein acidic and rich in cysteine; ST2, interleukin 1 receptor-like 1; sTNF1, soluble tumour necrosis factor receptor 1; Tie-2, tyrosine kinase with immunoglobulin-like and EGF-like domains 2; VCAM, vascular cell adhesion molecule; VEGF-1, vascular endothelial growth factor-1; vWF, von Willebrand factor.
Figure 3Graphic presentation of growth differentiation factor-15 (GDF-15), von Willebrand factor (vWF), vascular endothelial growth factor (VEGF)-1 and angiopoietin-2 during exercise and recovery with high and moderate intensity in the heart transplant recipients, with inserted P value for the analysis of variance interaction effect, exercise session×time. Level of significance: P value <0.1. HIT, high-intensity interval training; MICT, moderate-intensity continuous training.